Neurostimulators

Nyxoah Advances Genio Neurostimulator for OSA in Q3

Nyxoah SA reported a successful third quarter with clinical trial progress for its Genio neurostimulator system for the treatment of obstructive sleep apnea.

Neurostimulators

Remedē System Improves Life for Maryland Central Sleep Apnea Patient

A patient success story highlights how the remedē System, an FDA-approved implantable stimulator for central sleep apnea, enhanced the quality of life for Maryland's James Drake, 74.

Neurostimulators

FDA Grants Inspire AHI and BMI Increase

The update includes an increase on the upper limit of the apnea-hypopnea Index and raises the body mass index warning in the labeling.

Series of Regulatory Developments Define Inspire’s Q2 Landscape

Aug 2, 2023 | FDA, Neurostimulators, Obstructive Sleep Apnea

Inspire Medical Systems Inc reported second-quarter business results, marked by a series of US Food and Drug Administration regulatory approvals and submissions.

Inspire Appoints Chief Medical Officer

Jul 31, 2023 | Evolving Responsibilities, Neurostimulators, Obstructive Sleep Apnea

The newly appointed chief medical officer will serve full-time on Inspire’s executive leadership team and lead the company’s medical and clinical affairs functions.

Prosomnus to Compare Oral Appliance Therapy to Hypoglossal Nerve Stimulation in Clinical Trial

Jul 13, 2023 | Neurostimulators, Obstructive Sleep Apnea, Oral Appliances

ProSomnus announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation in treating patients with severe OSA.

Improving Care for Children with Down Syndrome and Sleep Apnea

Jun 30, 2023 | Age, Home Apnea Testing, Neurostimulators, Obstructive Sleep Apnea

Sleep apnea is common in children with Down syndrome. Sleep experts weigh in on what’s new in diagnosing and treating this patient population.

Brain Implant Being Tested for Dream Control

Jun 26, 2023 | Brain, Future of Sleep, Neurostimulators

With further development, the technology could allow people to control dream plots and induce lucid dreams, according to REMspace researchers.

Nyxoah Highlights Positive Early Findings from Neurostimulator Trial for Sleep Apnea

May 18, 2023 | Emerging Technology, Neurostimulators, Obstructive Sleep Apnea

The company has completed all 115 implants in the DREAM trial and expects full 12-month data in the first quarter of next year.

Inspire’s Q1 Business Results Highlight Progress in Sleep Apnea Therapy

May 3, 2023 | Neurostimulators, Obstructive Sleep Apnea

Inspire Medical Systems Inc, a medical technology company focused on the development of solutions...

Daytime Sleep Apnea Therapy eXciteOSA Surpasses 10,000 Patient Milestone

Mar 30, 2023 | Neurostimulators, Obstructive Sleep Apnea

Nasdaq recognized the milestone by congratulating Signifier Medical on the Nasdaq Tower in Times Square, New York.

Inspire Receives Reimbursement in Belgium for Sleep Apnea Therapy

Mar 14, 2023 | Neurostimulators, Obstructive Sleep Apnea

The reimbursement approval provides a pathway to open additional Inspire implanting centers in Belgium, while expanding access to care, according to Inspire Medical Systems.

Nyxoah Progresses in Neurostimulator Studies for Sleep Apnea

Mar 6, 2023 | Emerging Technology, Neurostimulators, Obstructive Sleep Apnea

The clinical and regulatory milestones bring Nyxoah closer to offering its Genio neurostimulator solution to OSA patients in the US, according to the company.

FDA Grants Breakthrough Designation to Inspire Medical for AHI & BMI Increase

Aug 4, 2022 | Neurostimulators, Obstructive Sleep Apnea

The FDA has granted Inspire Medical Inc Breakthrough Device Designation for a potential increase in the upper limit of AHI and BMI for patients to be eligible for Inspire Upper Airway Stimulation for obstructive sleep apnea.